The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

While there are a number of factors that can lead to constipation in over-60s, there are also many effective treatments.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.